Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CONTACT<br />
Eduardo Bravo (speaker)<br />
Managing Director and<br />
Chief Executive Officer<br />
ADDRESS<br />
TiGenix NV<br />
Haasrode Researchpark 1724<br />
Romeinse straat 12 bus 2<br />
3001 Leuven<br />
Belgium<br />
TELEPHONE<br />
+32 16 396 060<br />
FAX<br />
+32 16 397 970<br />
EMAIL<br />
eduardo.bravo@tigenix.com<br />
YEAR FOUNDED<br />
2000<br />
TiGenix NV<br />
www.tigenix.com<br />
COMPANY PROFILE<br />
TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and an<br />
advanced clinical stage pipeline of adult stem cell programs.<br />
The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the first and only approved<br />
cell-based product in Europe. The product has received full national reimbursement in Belgium and the<br />
Netherlands and is already being commercialized in 5 European countries.<br />
TiGenix’s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem<br />
cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages,<br />
they are being developed in close consultation with the European Medicines Agency. The company has initiated a<br />
Phase III clinical trial in complex perianal fistulas in patients with Crohn’s disease, has concluded recruitment in<br />
a Phase IIa trial in rheumatoid arthritis, and successfully concluded a Phase I trial to investigate the potential of<br />
intra-lymphatic administration of eASCs for autoimmune disorders.<br />
TiGenix is based out of Leuven (Belgium), and has operations in Madrid (Spain), and Sittard-Geleen (the<br />
Netherlands).<br />
MANAGEMENT<br />
Eduardo Bravo, Managing Director and Chief Executive Officer (CEO).<br />
Gil Beyen BVBA, Managing Director and Chief Business Officer (CBO)<br />
Claudia D’Augusta, Chief Financial Officer (CFO)<br />
Wilfried Dalemans, Chief Technical Officer (CTO)<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS